BTIG raised the firm’s price target on Vericel to $53 from $49 and keeps a Buy rating on the shares. The company is in a “very strong position” as it is at the front end of two major product launches in FY24, the analyst tells investors in a research note. Vericel is also generating immense profitability, has zero debt, and is benefiting from a strong orthopedic market environment, BTIG added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VCEL:
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
- Vericel price target raised to $49 from $41 at BTIG
- Tesla, Boeing downgraded: Wall Street’s top analyst calls
- Vericel upgraded to Buy from Hold at Truist
